Food and Drug Administration v Alliance for Hippocratic Medicine-A Cautious Win for Reproductive Health Care and FDA Authority

Michele B Goodwin; Allison M Whelan; Lawrence O Gostin

doi:10.1001/jama.2024.13161

Food and Drug Administration v Alliance for Hippocratic Medicine-A Cautious Win for Reproductive Health Care and FDA Authority

JAMA. 2024 Aug 13;332(6):453-454. doi: 10.1001/jama.2024.13161.

Authors

Michele B Goodwin¹, Allison M Whelan², Lawrence O Gostin¹

Affiliations

¹ O'Neill Institute for National and Global Health Law, Georgetown University Law Center, Washington, DC.
² Georgia State University College of Law, Atlanta.

PMID: 38913506
DOI: 10.1001/jama.2024.13161

No abstract available

Plain language summary

This Viewpoint discusses the recent US Supreme Court ruling allowing mifepristone—a drug used in medication abortion—to be widely available in the US, summarizes the history of challenges to the availability of mifepristone, and highlights reasons for concerns that remain after the Court’s current ruling.

MeSH terms

Abortifacient Agents, Steroidal / supply & distribution
Abortion, Induced* / legislation & jurisprudence
Abortion, Induced* / methods
Female
Health Services Accessibility* / legislation & jurisprudence
Humans
Mifepristone / supply & distribution
Patient Advocacy / legislation & jurisprudence
Pregnancy
Reproductive Health Services* / legislation & jurisprudence
United States
United States Food and Drug Administration* / legislation & jurisprudence

Substances

Mifepristone
Abortifacient Agents, Steroidal